BRAF mutations such as BRAFV600E and its fusion transcripts lead to constitutive activation of its Ser/Thr kinase activity and down-stream activation of RAF/MEK/ERK pathway in lung, melanoma, thyroid, and colon cancers7, 16, 17, 18, 19. Here, BRAF is linked to melanoma.